AT-7687 / Antag Therap - LARVOL DELTA

GIP receptor antagonism with AT7687 demonstrates promising safety and tolerability, predictable pharmacokinetics and metabolic target engagement in a first-in-human study (EASD 2026) - "AT7687 demonstrated good safety and tolerability, predictable pharmacokinetics and metabolic target engagement consistent with GIP receptor antagonism in humans. These findings support further development of AT7687 as a valid therapeutic component of future multipharmacological management of clinical obesity."

Clinical • First-in-human • P1 data • PK/PD data • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687 (GlobeNewswire) - "The Phase 2a study (NCT07724340) is a multi-center, randomized, double-blinded 13-week trial evaluating the safety and efficacy of AT7687 in combination with semaglutide for people living with overweight or obesity and type 2 diabetes who are not currently receiving anti-obesity medications. 150 participants will be randomized to receive either once-weekly subcutaneous injection of AT7687 weekly with semaglutide dose escalation, or placebo with semaglutide dose escalation, over a 13-week treatment period, followed by one-month safety follow-up....The study will be conducted in multiple sites in the United States, with topline results expected in H1 2027."

Trial status • Obesity • Type 2 Diabetes Mellitus

AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys (ADA 2026) - "Combining amylin/CTR agonism with GIPR antagonism yields supra-additive benefits on weight, body composition, and insulin sensitivity in obese, insulin-resistant NHPs. The decoupling between weight loss and energy intake suggests effects beyond appetite suppression. These findings support AT7687 as a differentiated, next-generation obesity therapy with additional promising benefits for patients requiring improved glycemic control."

Metabolic Disorders • Obesity

First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity (ADA 2026) - "Introduction and Objective: AT7687 is a first-in-class peptide GIPR antagonist validated as anti-obesity therapy in obese monkeys, as monotherapy and in combination with liraglutide and cagrilintide. AT7687 was well-tolerated, showed clinical evidence of potent GIPR antagonism, and encouraging trends of cardiometabolic benefits, justifying advancement into longer trials to assess its efficacy as monotherapy and as an ideal combination partner in obesity management."

First-in-human • P1 data • Metabolic Disorders • Obesity

Additionally, new preclinical data demonstrating the significant efficacy potential of combining AT7687 with cagrilintide in obese, insulin-resistant non-human primates (NHPs) was also presented. (GlobeNewswire) - "After a 42-day treatment period, the AT7687 and cagrilintide combination achieved a 12.2% body weight reduction from baseline, compared with 7.8% reduction with cagrilintide alone, demonstrating superior efficacy relative to monotherapy. This was accompanied by significantly improved insulin sensitivity, with the combination increasing glucose disappearance rate by 18.9%, compared with a 1.3% decline observed with cagrilintide monotherapy, further supporting the differentiated metabolic effects of GIPR antagonism and the potential for combination therapy to achieve superior efficacy versus monotherapy."

Preclinical • Obesity

The presentations included detailed results from the Company’s first-in-human study of AT7687, its first-in-class peptide-based glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist peptide, demonstrating that AT7687 was well-tolerated and suitable for once-weekly subcutaneous injection in people living with obesity. (GlobeNewswire) - "AT7687 demonstrated a favorable safety and tolerability profile across both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. No severe or serious adverse events were observed in the study and importantly, no gastrointestinal tolerability signals were identified, with GI adverse events reported as mild and similarly distributed between AT7687 and placebo arms...Pharmacokinetic analyses demonstrated dose-proportional exposure and low inter-subject variability consistent with once-weekly subcutaneous administration. Across both SAD and MAD cohorts, AT7687 demonstrated evidence of target engagement at all dose levels evaluated and in multiple organ systems. Collectively, these findings highlight the differentiated potential of AT7687 as a treatment for obesity and supports its continued advancement into Phase 2 clinical development....Antag is preparing to initiate a Phase 2a study of AT7687, which is expected to start in mid-2026."

First-in-human • New P2a trial • P1 data • Obesity

Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions (The Manila Times) - "The presentation will feature data from the Company’s first-in-human study of AT7687, its first-in-class Glucose Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist peptide, in both healthy subjects and people living with obesity...In addition to the oral presentation, the Company will present a poster highlighting preclinical data from its study assessing the therapeutic potential of combining AT7687 with cagrilintide, a dual amylin and calcitonin receptor (CTR) agonist with established weight-lowering efficacy....The AT7687 Phase 1 clinical trial has been successfully completed, and Phase 2a studies are expected to start in mid-2026."

First-in-human • New P2a trial • P1 data • Preclinical • Obesity

Amylin combination study (The Manila Times) - "The study was conducted in high-fat-fed obese, insulin-resistant NHPs which were randomized to placebo, cagrilintide, AT7687 or the combination for 42 days followed by a 15-day wash-out whilst fed ad libitum....AT7687 and cagrilintide combination regimen showed robust and sustained weight loss, in the low double-digit percentage range, without evidence that the effect plateaued over time. This weight loss effect was superior to that of either monotherapy treatment. Total energy intake was similar between animals receiving the combination and those treated with cagrilintide alone, indicating that the additional weight loss was not driven by reduced food intake. AT7687 alone or combined with cagrilintide was well tolerated."

Preclinical • Obesity

Phase 1 clinical study (The Manila Times) - "The study demonstrated a favorable safety and tolerability profile across all doses. No serious or severe adverse events and no discontinuations due to adverse events were reported. Notably, AT7687 demonstrated an excellent GI-related tolerability profile: all GI adverse events were mild and equally distributed between the AT7687 and the placebo arms. In addition, multi-organ target engagement was observed from the lowest tested doses, including reductions in LDL-cholesterol and resting heart rate. PK data were consistent with once-weekly subcutaneous dosing."

P1 data • Obesity

Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment (GlobeNewswire) - "Antag Therapeutics...today announces the initiation of its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist....The Phase 1a trial is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of AT-7687. It will be conducted in healthy lean and healthy subjects living with obesity, with topline results expected in Q4 2025....Following this study, the Company plans to investigate AT-7687 as a combination therapy in patients treated with a GLP-1 receptor agonist, with the study expected to commence at the end of 2025."

Trial status • Obesity

GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly. (PubMed, J Clin Endocrinol Metab) - "Of 25 patients with acromegaly, seven had paradoxical GH secretion during OGTT, and pharmaceutical GIPR blockade abolished this secretion in four. Corresponding somatotroph adenomas abundantly expressed GIPR, suggesting a therapeutic target in this subpopulation of patients. In vitro and ex vivo analyses confirmed the role of GIP and the effects of the antagonist."

Journal • Acromegaly • Endocrine Disorders • Pituitary Gland Carcinoma